- Home
- CRIS vs ABP Comparison
CRIS vs ABP Comparison
Compare CRIS & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | ABP |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | ABP |
|---|---|---|
| Price | $1.05 | $4.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 119.8K | 19.2K |
| Earning Date | 11-06-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,650,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.56 | ★ 50.00 |
| 52 Week Low | $1.02 | $4.54 |
| 52 Week High | $4.50 | $153.90 |
Technical Indicators
Market Signals| Indicator | CRIS | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 42.14 |
| Support Level | $1.14 | $4.55 |
| Resistance Level | $1.41 | $5.08 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 7.50 | 10.06 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.